- 1.
Mouton JW, Ambrose PG, Canton R et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14: 107–17. [PubMed][CrossRef]
- 2.
Mouton JW, Brown DF, Apfalter P et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37–45. [PubMed][CrossRef]
- 3.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10, quiz 11 - 2. [PubMed][CrossRef]
- 4.
Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79–86. [PubMed][CrossRef]
- 5.
Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601–7. [PubMed][CrossRef]
- 6.
Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498–509. [PubMed][CrossRef]
- 7.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Rationale Documents from EUCAST. http://www.eucast.org/documents/rd/ Lest 10.4.2020.
- 8.
Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis 2012; 54: 1785–92. [PubMed][CrossRef]
- 9.
Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clin Microbiol Infect 2015; 21: 881–5. [PubMed][CrossRef]
- 10.
Couet W. Pharmacokinetics/pharmacodynamics characterization of combined antimicrobial agents: a real challenge and an urgent need. Clin Microbiol Infect 2018; 24: 687–8. [PubMed][CrossRef]
- 11.
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance documents. Guidance on the 2019 modifications of susceptibility categories S, I and R categories. http://www.eucast.org Lest 2.9.2019.
- 12.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. Breakpoint tables for bacteria. http://www.eucast.org/clinical_breakpoints/ Lest 10.4.2020.
- 13.
Vinks A, Derendorf H, Mouton JW. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. New York, NY: Springer, 2014.
- 14.
Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: Which agents, which patients and which infections? Drugs 2018; 78: 439–51. [PubMed][CrossRef]
- 15.
Kashuba AD, Nafziger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623–9. [PubMed][CrossRef]
- 16.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9. [PubMed][CrossRef]
- 17.
Pagkalis S, Mantadakis E, Mavros MN et al. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 2011; 71: 2277–94. [PubMed][CrossRef]
- 18.
Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598–606. [PubMed][CrossRef]
- 19.
Fjeld H, Stylianou E. Hypersensitivity reactions with prolonged infusions of β-lactams? Clin Microbiol Infect 2019; 25: 121–2. [PubMed][CrossRef]
- 20.
Heffernan AJ, Sime FB, Lipman J et al. Individualising therapy to minimize bacterial multidrug resistance. Drugs 2018; 78: 621–41. [PubMed][CrossRef]
- 21.
Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand 2017; 61: 627–35. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.